Comparison of Sitagliptin vs Conventional therapy On Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes

Trial Profile

Comparison of Sitagliptin vs Conventional therapy On Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 08 Dec 2014

At a glance

  • Drugs Sitagliptin (Primary)
  • Indications Coronary arteriosclerosis; Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Acronyms SCOOP
  • Most Recent Events

    • 12 Jul 2013 Planned End Date changed from 1 Mar 2014 to 31 Mar 2015 as reported by University Hospital Medical Information Network - Japan.
    • 24 Aug 2012 Planned End Date added to 1 Mar 2014 as reported by University Hospital Medical Information Network - Japan.
    • 06 Jun 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top